Literature DB >> 12584346

Genetic characterization of rebounding human immunodeficiency virus type 1 in plasma during multiple interruptions of highly active antiretroviral therapy.

Mark Dybul1, Marybeth Daucher, Mark A Jensen, Claire W Hallahan, Tae-Wook Chun, Michael Belson, Bertha Hidalgo, David C Nickle, Christian Yoder, Julia A Metcalf, Richard T Davey, Linda Ehler, Diane Kress-Rock, Elizabeth Nies-Kraske, Shuying Liu, James I Mullins, Anthony S Fauci.   

Abstract

Various strategies of interrupting highly active antiretroviral therapy (HAART) are being investigated for the treatment of human immunodeficiency virus (HIV) infection. Interruptions of greater than 2 weeks frequently result in rebound of plasma HIV RNA. In order to discern changes in the viral population that might occur during cycles of treatment interruption, we evaluated the homology of HIV-1 envelope gene sequences over time in 12 patients who received four to seven cycles of 4 weeks off HAART followed by 8 weeks on HAART by using the heteroduplex tracking assay and novel statistical tools. HIV populations in 9 of 12 patients diverged from those found in the first cycle in at least one subsequent cycle. The substantial genetic changes noted in HIV env did not correlate with increased or decreased log changes in levels of plasma HIV RNA (P > 0.5). Thus, genetic changes in HIV env itself did not contribute in a systematic way to changes in levels of plasma viremia from cycle to cycle of treatment interruption. In addition, the data suggest that there may be multiple compartments contributing to the rebound of plasma viremia and to viral diversity from cycle to cycle of intermittent therapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12584346      PMCID: PMC149739          DOI: 10.1128/jvi.77.5.3229-3237.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  42 in total

1.  Public health. HIV/AIDS treatment for millions.

Authors:  H P Binswanger
Journal:  Science       Date:  2001-04-13       Impact factor: 47.728

2.  Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects.

Authors:  G M Ortiz; M Wellons; J Brancato; H T Vo; R L Zinn; D E Clarkson; K Van Loon; S Bonhoeffer; G D Miralles; D Montefiori; J A Bartlett; D F Nixon
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-30       Impact factor: 11.205

3.  Less is more? STI in acute and chronic HIV-1 infection.

Authors:  M Altfeld; B D Walker
Journal:  Nat Med       Date:  2001-08       Impact factor: 53.440

4.  The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection.

Authors:  F García; M Plana; G M Ortiz; S Bonhoeffer; A Soriano; C Vidal; A Cruceta; M Arnedo; C Gil; G Pantaleo; T Pumarola; T Gallart; D F Nixon; J M Miró; J M Gatell
Journal:  AIDS       Date:  2001-06-15       Impact factor: 4.177

5.  HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection.

Authors:  L Ruiz; G Carcelain; J Martínez-Picado; S Frost; S Marfil; R Paredes; J Romeu; E Ferrer; K Morales-Lopetegi; B Autran; B Clotet
Journal:  AIDS       Date:  2001-06-15       Impact factor: 4.177

6.  Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy.

Authors:  D Finzi; M Hermankova; T Pierson; L M Carruth; C Buck; R E Chaisson; T C Quinn; K Chadwick; J Margolick; R Brookmeyer; J Gallant; M Markowitz; D D Ho; D D Richman; R F Siliciano
Journal:  Science       Date:  1997-11-14       Impact factor: 47.728

7.  Replication and compartmentalization of HIV-1 in kidney epithelium of patients with HIV-associated nephropathy.

Authors:  Daniele Marras; Leslie A Bruggeman; Feng Gao; Nozomu Tanji; Mahesh M Mansukhani; Andrea Cara; Michael D Ross; G Luca Gusella; Gary Benson; Vivette D D'Agati; Beatrice H Hahn; Mary E Klotman; Paul E Klotman
Journal:  Nat Med       Date:  2002-05       Impact factor: 53.440

8.  Rapid, transient changes at the env locus of plasma human immunodeficiency virus type 1 populations during the emergence of protease inhibitor resistance.

Authors:  E L Delwart; H Pan; A Neumann; M Markowitz
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

9.  Human immunodeficiency virus type 1 populations in blood and semen.

Authors:  E L Delwart; J I Mullins; P Gupta; G H Learn; M Holodniy; D Katzenstein; B D Walker; M K Singh
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

10.  Visceral abdominal-fat accumulation associated with use of indinavir.

Authors:  K D Miller; E Jones; J A Yanovski; R Shankar; I Feuerstein; J Falloon
Journal:  Lancet       Date:  1998-03-21       Impact factor: 79.321

View more
  18 in total

1.  Subpopulations of equine infectious anemia virus Rev coexist in vivo and differ in phenotype.

Authors:  Prasith Baccam; Robert J Thompson; Yuxing Li; Wendy O Sparks; Michael Belshan; Karin S Dorman; Yvonne Wannemuehler; J Lindsay Oaks; James L Cornette; Susan Carpenter
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

2.  Indinavir resistance evolution in one human immunodeficiency virus type 1 infected patient revealed by single-genome amplification.

Authors:  Qing-Mao Geng; Han-Ping Li; Zuo-Yi Bao; Yong-Jian Liu; Dao-Min Zhuang; Lin Li; Si-Yang Liu; Jing-Yun Li
Journal:  Virol Sin       Date:  2010-10-08       Impact factor: 4.327

3.  A reliable phenotype predictor for human immunodeficiency virus type 1 subtype C based on envelope V3 sequences.

Authors:  Mark A Jensen; Mia Coetzer; Angélique B van 't Wout; Lynn Morris; James I Mullins
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

4.  Phylogenetic Analyses Comparing HIV Sequences from Plasma at Virologic Failure to Cervix Versus Blood Sequences from Antecedent Antiretroviral Therapy Suppression.

Authors:  Marta E Bull; Jennifer L McKernan; Sheila Styrchak; Kelli Kraft; Jane Hitti; Susan E Cohn; Kenneth Tapia; Wenjie Deng; Sarah Holte; James I Mullins; Robert W Coombs; Lisa M Frenkel
Journal:  AIDS Res Hum Retroviruses       Date:  2019-04-30       Impact factor: 2.205

5.  The gut mucosal viral reservoir in HIV-infected patients is not the major source of rebound plasma viremia following interruption of highly active antiretroviral therapy.

Authors:  Paula Lerner; Moraima Guadalupe; Richard Donovan; Jason Hung; Jason Flamm; Thomas Prindiville; Sumathi Sankaran-Walters; Michael Syvanen; Joseph K Wong; Michael D George; Satya Dandekar
Journal:  J Virol       Date:  2011-02-23       Impact factor: 5.103

6.  Evidence that low-level viremias during effective highly active antiretroviral therapy result from two processes: expression of archival virus and replication of virus.

Authors:  Nicole H Tobin; Gerald H Learn; Sarah E Holte; Yang Wang; Ann J Melvin; Jennifer L McKernan; Diane M Pawluk; Kathleen M Mohan; Paul F Lewis; James I Mullins; Lisa M Frenkel
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

7.  A novel assay allows genotyping of the latent reservoir for human immunodeficiency virus type 1 in the resting CD4+ T cells of viremic patients.

Authors:  Daphne Monie; Rachel P Simmons; Richard E Nettles; Tara L Kieffer; Yan Zhou; Haili Zhang; Sharon Karmon; Roxann Ingersoll; Karen Chadwick; Hao Zhang; Joseph B Margolick; Thomas C Quinn; Stuart C Ray; Megan Wind-Rotolo; Michael Miller; Deborah Persaud; Robert F Siliciano
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

Review 8.  Molecular mechanisms of HIV-1 persistence in the monocyte-macrophage lineage.

Authors:  Valentin Le Douce; Georges Herbein; Olivier Rohr; Christian Schwartz
Journal:  Retrovirology       Date:  2010-04-09       Impact factor: 4.602

Review 9.  Modeling HIV persistence, the latent reservoir, and viral blips.

Authors:  Libin Rong; Alan S Perelson
Journal:  J Theor Biol       Date:  2009-06-17       Impact factor: 2.691

10.  Increased mutations in Env and Pol suggest greater HIV-1 replication in sputum-derived viruses compared with blood-derived viruses.

Authors:  Thor A Wagner; Nicole H Tobin; Jennifer L McKernan; Min Xu; Ann J Melvin; Kathleen M Mohan; Gerald H Learn; James I Mullins; Lisa M Frenkel
Journal:  AIDS       Date:  2009-05-15       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.